Figure 6

Anti-CD52 therapy restricts tumor growth. A(1). Tumor growth curves for control and anti-CD52 treated (n = 10 per group in duplicate experiments) subcutaneous ID8-VEGF ovarian tumors. Tumor growth was significantly restricted with anti-CD52 therapy (p = 0.01). B. Representative sections of CD31 IHC and lectin perfusion labeling of ID8 flank tumors demonstrating significant reduction in tumor penetrating vessels and vascular perfusion in control and CD52-treated tumors. Magnification and scale bars as indicated. C. Quantification of microvascular density in anti-CD52 treated tumors and control tumors assessed by CD31 IHC. D. Kaplan Meier survival plots for control and anti-CD52 immunotoxin treated animals (n = 10/group) using an orthotopic intraperitoneal ID8 tumor model. Overall survival was significantly increased by anti-CD52 therapy (p = 0.03).